DHCPL
Communicating safety information to patients and healthcare professionals is a public health responsibility, and is essential in promoting the safe and rational use of medicines, and preventing harm from adverse reactions.
This webpage serves to provide the public and healthcare professionals with easy access to important drug safety information, as approved by SAHPRA. Safety alerts provide important information and recommendations about therapeutic products; however, it does not necessarily imply that a product is considered unsafe.
Fluracedyl 250/500/1000/5000
Fluoropyrimidine containing medicines and related substances: increased drug exposure and toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency.
View PDFTeva Carbilevo 25/100; 25/250
Dopaminergic medicines used in the treatment of Parkinson’s Disease: risk of dopamine dysregulation syndrome (DDS).
View PDFCiprol 250/500
Fluoroquinolone antibiotics: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones.
View PDFLokit
Increased risk of subclinical acute interstitial nephritis associated with the use of proton pump inhibitors (PPIs) leading to acute kidney injury and/or chronic renal failure.
View PDFNurika 25/50/75/150; Pregabalin Ivax 25/50/75/150
This relates to the risk of serious breathing difficulty associated with the use of gabapentinoids (gabapentin and pregabalin).
View PDFBupyra XL 150/300
This relates to the risk of Brugada syndrome associated with the use of bupropion-containing medicines.
View PDF